18F-Fluorodeoxyglucose-positron Emission Tomography/Computed Tomography-Guided Chest Radiotherapy Improves Survival in Patients with Extracranial Oligometastatic Non-small Cell Lung Cancer

Tianlu Wang,Chengsen Liu,Yingqiu Song,Zheng Wang,Lei He,Chenyu Wang,Yu Wu,Ye Wang,Xiaofang Zhang,Guang Li
DOI: https://doi.org/10.21203/rs.3.rs-1292014/v1
2022-01-01
Abstract:Abstract Background This retrospective study compared positron emission tomography (PET)/computed tomography (CT) and CT in the treatment of extracranial oligometastatic non-small-cell lung cancer (NSCLC) and explored the impact of chest radiotherapy (CRT) on patient survival. Methods We reviewed the medical records of Chinese patients with stage IV extracranial oligometastatic NSCLC who underwent PET/CT or CT at two centers. Propensity score matching (PSM) was used to control differences in patient characteristics between the maintenance chemotherapy alone and CRT plus maintenance chemotherapy groups. Results We analyzed 192 eligible patients. The median survival time was significantly longer in the CRT plus maintenance group than in the chemotherapy alone group (13 months vs. 8 months, p < 0.001). Subgroup analysis showed no statistical difference in survival between both groups in patients who underwent CT examinations (n=98, 8 months vs. 5 months, p = 0.180). However, differences in survival between both groups were statistically significant in patients who underwent PET/CT examinations (n=94, 25 months vs. 11 months, p < 0.001). A multifactorial analysis revealed a more favorable prognosis in patients who underwent PET/CT evaluation (HR: 0.343, 95% CI: 0.250-0.471, p < 0.001) and CRT (HR: 0.624, 95% CI: 0.464-0.840, p = 0.002) than in those who did not. The conclusion obtained after PSM is consistent with the above mentioned results. Conclusions PET/CT-guided CRT is associated with improved clinical outcomes in patients with stage IV extracranial oligometastatic NSCLC.
What problem does this paper attempt to address?